Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04471727Phase 1Active Not Recruiting

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Role: lead

NCT04184050Phase 1Active Not Recruiting

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

Role: lead

NCT03872206Phase 1Completed

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Role: lead

NCT03577028Phase 1Terminated

Study of HPN424 in Patients With Advanced Prostate Cancer

Role: lead

All 4 trials loaded